Posters

  • RX-3117, An Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer [(PDF File) Sunday, September 10, 2017, 8:15am]
    (2017 European Society for Medical Oncology (ESMO) Congress – Madrid, Spain, September 8-12, 2017)
  • Phase 1 study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents β-catenin Translocation in Advanced Solid Tumors [(PDF File) Monday, September 11, 2017, 8:15am]
    (2017 European Society for Medical Oncology (ESMO) Congress – Madrid, Spain, September 8-12, 2017)
  • A Novel Small Molecule Nucleoside Analog, RX-3117, Shows Potent Therapeutic Activity in Combination with Nab-paclitaxel and Checkpoint Inhibitors in Xenograft Models [(PDF File) Monday, September 11, 2017, 8:15am]
    (2017 European Society for Medical Oncology (ESMO) Congress – Madrid, Spain, September 8-12, 2017)
  • Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ib/IIa study. [PDF file]
    ( American Society of Clinical Oncology (ASCO) 2017 Annual Meeting – Chicago, Il, Jun 2–6, 2017)
  • RX3117, An Oral Antimetabolite Nucleoside Shows Activity in Subjects with Pancreatic Cancer. Preliminary Results of Stage 1 of the Phase 1a/2b Study [PDF file]
    (Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, CA, Jan 19 –21, 2017)
  • RX-3117, An Oral Antimetabolite to Treat Advanced Solid Tumors (ST): Phase 1 and Ongoing Phase 2a Results [PDF file]
    Phase 1/2a Study of RX-5902 in Advanced Solid Tumors (ST): an Orally Bioavailable Inhibitor of Phosphorylated p68 and Modulator of β-Catenin Nuclear Translocation [PDF file]
    (Presented at the ESMO 2016 Congress From disease treatment to patient care, Oct 7 – 11, 2016)
  • Phase Ib/II Study of RX-0201, a Novel AKT-1 Antisense Combined with Everolimus to Treat Metastatic Renal Cell Carcinoma – Phase Ib Results [PDF file]
    Folate Receptor-Targeted Lipid Coated Albumin Nanoparticles (F-LCAN) for Therapeutic Delivery of RX-0201 (Archexin®), an Antisense Oligonucleotide Against AKT-1 [PDF file]
    Inhibition of DNA Methyltransferase by RX-3117 Leads to Upregulation of Hypomethylated Targets [PDF file]
    (Presented at American Association for Cancer Research (AACR) 107th Annual Meeting, Apr 16 – 20, 2016)
  • RX-5902 a Phosphorylated p68 Targeting Agent to Treat Subjects with Advanced Solid Tumors [PDF file]
    The Anticancer Effects of Supinoxin (RX-5902) in Pancreatic Cancer [PDF file]
    (Presented at the ASCO Gastrointestinal Cancers Symposium, Jan 21 – 23, 2016)
  • Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data [PDF file]
    The Anticancer Effects of Supinoxin(RX-5902) in Renal Cell Cancer [PDF file]
    (Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, CA, Jan 7 – 9, 2016)
  • New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer
    (Presented at The 38th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Dec 8 – 10, 2015) [PDF file]
  • RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer – Preliminary Stage 1 Data
    (Presented at the 14th Annual Kidney Cancer Symposium, Miami, FL, Nov 6 – 7, 2015) [PDF file]
    • Single Agent Supinoxin Targeting Phosphorylated p-68, Preliminary Phase I Data
      (Presented at the 2015 The European Cancer Congress (ECC 2015) Annual Meeting, Vienna, Austria, Sep 25 – 29, 2015) [PDF file]

 

    • Preliminary phase 1 data of single agent RX-3117, an oral antimetabolite nucleoside
      (Presented at the 2015 The European Cancer Congress (ECC 2015) Annual Meeting, Vienna, Austria, Sep 25 – 29, 2015) [PDF file]

 

    • A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors
      (Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015) [PDF file]

 

    • A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors
      (Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015) [PDF file]

 

    • A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma
      (Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015) [PDF file]

 

    • A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors
      (Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, May 29 – June 2, 2015) [PDF file]

 

    • Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker
      (Presented at the American Association for Cancer Research (AACR) 106th Annual Meeting, Philadelphia, Pennsylvania, April 18-22, 2015) [PDF file]

 

    • Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)
      (Presented at the American Association for Cancer Research (AACR) 106th Annual Meeting, Philadelphia, Pennsylvania, April 18-22, 2015) [PDF file]

 

    • A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine
      (Presented at the American Association for Cancer Research (AACR) 105th Annual Meeting, San Diego, California, April 5-9, 2014) [PDF file]

 

    • Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy
      (Presented at the American Association for Cancer Research (AACR) 105th Annual Meeting, San Diego, California, April 5-9, 2014) [PDF file]

 

    • Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902)
      (Presented at the American Association for Cancer Research (AACR) 104th Annual Meeting, Washington, D.C., April 6-10, 2013) [PDF file]

 

    • Anti-tumor activity of a new quinoxalinyl-piperazine compound (RX-5902)
      (Present data on novel Anti-Cancer Small Molecule RX-5902 at AACR 102nd Annual Meeting, Orlando, FL, April 2-6, 2011) [PDF file]

 

    • Characterization of a novel small molecule with potent anticancer activity (RX-8243)
      (Presented at the American Association for Cancer Research (AACR) 101st Annual Meeting, Washington, D.C., April 17-21, 2010) [PDF file]

 

  • A Phase I Trial of RX-0201 (Archexin; akt-1 Antisense) in Patients with An Advanced Cancer
    (Presented at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2007) [PDF file]